Puma Biotech (PBYI), Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St slides as oil tops $100, yields hit 2023 high; Apple down before Ternus' first launch event as CEO
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Oil nears $100 as fresh Middle East strikes raise supply risks
- How big a risk are rates to the AI boom?
- 3 reasons why S&P 500 may drop up to 10% in the near term: RBC
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China
February 25, 2021 4:07 PM ESTPuma Biotechnology and CANbridge Pharmaceuticals Terminate License Agreement in Greater China
LOS ANGELES & CASTRES, France--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX® (neratinib) within Europe, Turkey, Middle East and Africa. The amended agreement extends Pierre Fabres commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and... More
